Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

3 Bargain Basement Tech Stocks Worth Speculating On

By Josh Enomoto, InvestorPlace Contributor

Everybody loves Nvidia (NASDAQ:NVDA) and company, but let’s be real – the concept of bargain tech stocks makes a lot of sense. At the end…

Epic Crypto Comebacks: 7 Coins Set for a Bullish Breakthrough

By Josh Enomoto, InvestorPlace Contributor

I’m just going to give it to you straight – many cryptos are printing or have printed overheated technical metrics. Based on historical trends, a…

Dear LUNR Stock Fans, Mark Your Calendars for Feb. 22

By Josh Enomoto, InvestorPlace Contributor

As Intuitive Machines continues to hit milestones, LUNR stock has skyrocketed. However, not everyone is convinced.

Bold Bets: 7 ‘Black Sheep’ Stock Picks for the Maverick Investor

By Josh Enomoto, InvestorPlace Contributor

While the conventional methodology exists for a reason, sometimes, you need maverick stocks to shake things up. These ideas may be odd but they may…

Why Is Iovance Therapeutics (IOVA) Stock Up 35% Today?

By Josh Enomoto, InvestorPlace Contributor

With Iovance Therapeutics gaining FDA approval for its novel skin cancer therapeutic, IOVA stock is proving the bears wrong.

Load More